newsfilter
← Latest News
GlobeNewswire·

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1Long-term seizure reduction with a median reduction of 82% at 3 years.Seizure